nodes	percent_of_prediction	percent_of_DWPC	metapath
Vandetanib—ABCG2—primary biliary cirrhosis	0.302	0.696	CbGaD
Vandetanib—ALB—primary biliary cirrhosis	0.132	0.304	CbGaD
Vandetanib—ABCC1—Colchicine—primary biliary cirrhosis	0.108	0.699	CbGbCtD
Vandetanib—CYP3A4—Chenodeoxycholic acid—primary biliary cirrhosis	0.0309	0.2	CbGbCtD
Vandetanib—CYP3A4—Colchicine—primary biliary cirrhosis	0.0156	0.101	CbGbCtD
Vandetanib—ORM1—bile—primary biliary cirrhosis	0.00654	0.102	CbGeAlD
Vandetanib—Anuria—Colchicine—primary biliary cirrhosis	0.00406	0.0248	CcSEcCtD
Vandetanib—Pericarditis—Chenodeoxycholic acid—primary biliary cirrhosis	0.00294	0.018	CcSEcCtD
Vandetanib—Pericarditis—Ursodeoxycholic acid—primary biliary cirrhosis	0.00294	0.018	CcSEcCtD
Vandetanib—Blood glucose increased—Chenodeoxycholic acid—primary biliary cirrhosis	0.00249	0.0152	CcSEcCtD
Vandetanib—Blood glucose increased—Ursodeoxycholic acid—primary biliary cirrhosis	0.00249	0.0152	CcSEcCtD
Vandetanib—Bosutinib—RPS6KB1—primary biliary cirrhosis	0.00224	0.392	CrCbGaD
Vandetanib—BMPR1B—epithelium—primary biliary cirrhosis	0.00223	0.0349	CbGeAlD
Vandetanib—Cholecystitis—Ursodeoxycholic acid—primary biliary cirrhosis	0.00222	0.0136	CcSEcCtD
Vandetanib—Cholecystitis—Chenodeoxycholic acid—primary biliary cirrhosis	0.00222	0.0136	CcSEcCtD
Vandetanib—Hypothyroidism—Colchicine—primary biliary cirrhosis	0.00221	0.0135	CcSEcCtD
Vandetanib—Polyp—Chenodeoxycholic acid—primary biliary cirrhosis	0.00209	0.0128	CcSEcCtD
Vandetanib—Polyp—Ursodeoxycholic acid—primary biliary cirrhosis	0.00209	0.0128	CcSEcCtD
Vandetanib—PDGFRB—gall bladder—primary biliary cirrhosis	0.00194	0.0303	CbGeAlD
Vandetanib—Cyst—Chenodeoxycholic acid—primary biliary cirrhosis	0.0019	0.0117	CcSEcCtD
Vandetanib—Cyst—Ursodeoxycholic acid—primary biliary cirrhosis	0.0019	0.0117	CcSEcCtD
Vandetanib—ORM1—gall bladder—primary biliary cirrhosis	0.00182	0.0284	CbGeAlD
Vandetanib—Interstitial lung disease—Chenodeoxycholic acid—primary biliary cirrhosis	0.0018	0.011	CcSEcCtD
Vandetanib—Interstitial lung disease—Ursodeoxycholic acid—primary biliary cirrhosis	0.0018	0.011	CcSEcCtD
Vandetanib—FLT4—epithelium—primary biliary cirrhosis	0.00176	0.0275	CbGeAlD
Vandetanib—RIPK2—epithelium—primary biliary cirrhosis	0.00175	0.0274	CbGeAlD
Vandetanib—VEGFA—smooth muscle tissue—primary biliary cirrhosis	0.00168	0.0263	CbGeAlD
Vandetanib—ERBB3—epithelium—primary biliary cirrhosis	0.00168	0.0262	CbGeAlD
Vandetanib—Skin ulcer—Chenodeoxycholic acid—primary biliary cirrhosis	0.00164	0.01	CcSEcCtD
Vandetanib—Skin ulcer—Ursodeoxycholic acid—primary biliary cirrhosis	0.00164	0.01	CcSEcCtD
Vandetanib—ALB—gall bladder—primary biliary cirrhosis	0.00159	0.0249	CbGeAlD
Vandetanib—RET—epithelium—primary biliary cirrhosis	0.00155	0.0243	CbGeAlD
Vandetanib—Acne—Ursodeoxycholic acid—primary biliary cirrhosis	0.00151	0.00927	CcSEcCtD
Vandetanib—Acne—Chenodeoxycholic acid—primary biliary cirrhosis	0.00151	0.00927	CcSEcCtD
Vandetanib—AXL—smooth muscle tissue—primary biliary cirrhosis	0.00149	0.0233	CbGeAlD
Vandetanib—Creatinine increased—Colchicine—primary biliary cirrhosis	0.00149	0.00912	CcSEcCtD
Vandetanib—TEK—epithelium—primary biliary cirrhosis	0.00142	0.0221	CbGeAlD
Vandetanib—Cellulitis—Chenodeoxycholic acid—primary biliary cirrhosis	0.0014	0.00858	CcSEcCtD
Vandetanib—Cellulitis—Ursodeoxycholic acid—primary biliary cirrhosis	0.0014	0.00858	CcSEcCtD
Vandetanib—FYN—smooth muscle tissue—primary biliary cirrhosis	0.0014	0.0218	CbGeAlD
Vandetanib—TEK—smooth muscle tissue—primary biliary cirrhosis	0.00136	0.0213	CbGeAlD
Vandetanib—MAP4K5—smooth muscle tissue—primary biliary cirrhosis	0.00136	0.0213	CbGeAlD
Vandetanib—Blood bilirubin increased—Chenodeoxycholic acid—primary biliary cirrhosis	0.00135	0.00824	CcSEcCtD
Vandetanib—Blood bilirubin increased—Ursodeoxycholic acid—primary biliary cirrhosis	0.00135	0.00824	CcSEcCtD
Vandetanib—Cataract—Chenodeoxycholic acid—primary biliary cirrhosis	0.00134	0.00819	CcSEcCtD
Vandetanib—Cataract—Ursodeoxycholic acid—primary biliary cirrhosis	0.00134	0.00819	CcSEcCtD
Vandetanib—Creatinine increased—Ursodeoxycholic acid—primary biliary cirrhosis	0.00134	0.00819	CcSEcCtD
Vandetanib—Creatinine increased—Chenodeoxycholic acid—primary biliary cirrhosis	0.00134	0.00819	CcSEcCtD
Vandetanib—Afatinib—ABCG2—primary biliary cirrhosis	0.00131	0.23	CrCbGaD
Vandetanib—LYN—liver—primary biliary cirrhosis	0.00128	0.0201	CbGeAlD
Vandetanib—Bladder pain—Colchicine—primary biliary cirrhosis	0.00128	0.00785	CcSEcCtD
Vandetanib—YES1—smooth muscle tissue—primary biliary cirrhosis	0.00126	0.0197	CbGeAlD
Vandetanib—SRC—epithelium—primary biliary cirrhosis	0.00126	0.0197	CbGeAlD
Vandetanib—Cystitis noninfective—Chenodeoxycholic acid—primary biliary cirrhosis	0.00124	0.00762	CcSEcCtD
Vandetanib—Cystitis noninfective—Ursodeoxycholic acid—primary biliary cirrhosis	0.00124	0.00762	CcSEcCtD
Vandetanib—Cystitis—Ursodeoxycholic acid—primary biliary cirrhosis	0.00123	0.00753	CcSEcCtD
Vandetanib—Cystitis—Chenodeoxycholic acid—primary biliary cirrhosis	0.00123	0.00753	CcSEcCtD
Vandetanib—SRC—smooth muscle tissue—primary biliary cirrhosis	0.00121	0.0189	CbGeAlD
Vandetanib—KDR—epithelium—primary biliary cirrhosis	0.00116	0.0181	CbGeAlD
Vandetanib—Bladder pain—Ursodeoxycholic acid—primary biliary cirrhosis	0.00115	0.00705	CcSEcCtD
Vandetanib—Neoplasm—Chenodeoxycholic acid—primary biliary cirrhosis	0.00115	0.00705	CcSEcCtD
Vandetanib—Neoplasm—Ursodeoxycholic acid—primary biliary cirrhosis	0.00115	0.00705	CcSEcCtD
Vandetanib—Bladder pain—Chenodeoxycholic acid—primary biliary cirrhosis	0.00115	0.00705	CcSEcCtD
Vandetanib—KDR—smooth muscle tissue—primary biliary cirrhosis	0.00111	0.0174	CbGeAlD
Vandetanib—FLT3—liver—primary biliary cirrhosis	0.0011	0.0172	CbGeAlD
Vandetanib—STK35—liver—primary biliary cirrhosis	0.00108	0.0168	CbGeAlD
Vandetanib—ABL2—liver—primary biliary cirrhosis	0.00105	0.0164	CbGeAlD
Vandetanib—Gastrointestinal haemorrhage—Colchicine—primary biliary cirrhosis	0.00103	0.0063	CcSEcCtD
Vandetanib—EGFR—liver—primary biliary cirrhosis	0.00102	0.016	CbGeAlD
Vandetanib—PDGFRB—epithelium—primary biliary cirrhosis	0.001	0.0157	CbGeAlD
Vandetanib—FLT4—liver—primary biliary cirrhosis	0.000997	0.0156	CbGeAlD
Vandetanib—RIPK2—liver—primary biliary cirrhosis	0.000992	0.0155	CbGeAlD
Vandetanib—VEGFA—liver—primary biliary cirrhosis	0.000989	0.0155	CbGeAlD
Vandetanib—FMO1—liver—primary biliary cirrhosis	0.000984	0.0154	CbGeAlD
Vandetanib—Atrial fibrillation—Chenodeoxycholic acid—primary biliary cirrhosis	0.000975	0.00597	CcSEcCtD
Vandetanib—Atrial fibrillation—Ursodeoxycholic acid—primary biliary cirrhosis	0.000975	0.00597	CcSEcCtD
Vandetanib—IRAK4—liver—primary biliary cirrhosis	0.000969	0.0151	CbGeAlD
Vandetanib—PDGFRB—smooth muscle tissue—primary biliary cirrhosis	0.000965	0.0151	CbGeAlD
Vandetanib—Blood creatinine increased—Colchicine—primary biliary cirrhosis	0.000964	0.0059	CcSEcCtD
Vandetanib—Dehydration—Colchicine—primary biliary cirrhosis	0.000957	0.00586	CcSEcCtD
Vandetanib—ERBB3—liver—primary biliary cirrhosis	0.00095	0.0148	CbGeAlD
Vandetanib—Cardiac failure—Ursodeoxycholic acid—primary biliary cirrhosis	0.000947	0.0058	CcSEcCtD
Vandetanib—Cardiac failure—Chenodeoxycholic acid—primary biliary cirrhosis	0.000947	0.0058	CcSEcCtD
Vandetanib—Erlotinib—ABCG2—primary biliary cirrhosis	0.000928	0.162	CrCbGaD
Vandetanib—Gastrointestinal haemorrhage—Chenodeoxycholic acid—primary biliary cirrhosis	0.000924	0.00566	CcSEcCtD
Vandetanib—Gastrointestinal haemorrhage—Ursodeoxycholic acid—primary biliary cirrhosis	0.000924	0.00566	CcSEcCtD
Vandetanib—Alanine aminotransferase increased—Colchicine—primary biliary cirrhosis	0.000907	0.00556	CcSEcCtD
Vandetanib—MKNK1—liver—primary biliary cirrhosis	0.000891	0.0139	CbGeAlD
Vandetanib—FGR—liver—primary biliary cirrhosis	0.000881	0.0138	CbGeAlD
Vandetanib—LCK—liver—primary biliary cirrhosis	0.000881	0.0138	CbGeAlD
Vandetanib—AXL—liver—primary biliary cirrhosis	0.000877	0.0137	CbGeAlD
Vandetanib—Blood creatinine increased—Chenodeoxycholic acid—primary biliary cirrhosis	0.000866	0.0053	CcSEcCtD
Vandetanib—Blood creatinine increased—Ursodeoxycholic acid—primary biliary cirrhosis	0.000866	0.0053	CcSEcCtD
Vandetanib—ABL1—smooth muscle tissue—primary biliary cirrhosis	0.00086	0.0134	CbGeAlD
Vandetanib—Dehydration—Chenodeoxycholic acid—primary biliary cirrhosis	0.000859	0.00526	CcSEcCtD
Vandetanib—Dehydration—Ursodeoxycholic acid—primary biliary cirrhosis	0.000859	0.00526	CcSEcCtD
Vandetanib—FMO3—liver—primary biliary cirrhosis	0.00085	0.0133	CbGeAlD
Vandetanib—SLK—liver—primary biliary cirrhosis	0.000844	0.0132	CbGeAlD
Vandetanib—Neutropenia—Colchicine—primary biliary cirrhosis	0.000831	0.00509	CcSEcCtD
Vandetanib—FYN—liver—primary biliary cirrhosis	0.000821	0.0128	CbGeAlD
Vandetanib—Gastritis—Chenodeoxycholic acid—primary biliary cirrhosis	0.000818	0.00501	CcSEcCtD
Vandetanib—Gastritis—Ursodeoxycholic acid—primary biliary cirrhosis	0.000818	0.00501	CcSEcCtD
Vandetanib—Alanine aminotransferase increased—Chenodeoxycholic acid—primary biliary cirrhosis	0.000815	0.00499	CcSEcCtD
Vandetanib—Alanine aminotransferase increased—Ursodeoxycholic acid—primary biliary cirrhosis	0.000815	0.00499	CcSEcCtD
Vandetanib—TEK—liver—primary biliary cirrhosis	0.000802	0.0125	CbGeAlD
Vandetanib—MAP4K5—liver—primary biliary cirrhosis	0.000802	0.0125	CbGeAlD
Vandetanib—Dysphagia—Chenodeoxycholic acid—primary biliary cirrhosis	0.000799	0.00489	CcSEcCtD
Vandetanib—Influenza—Chenodeoxycholic acid—primary biliary cirrhosis	0.000799	0.00489	CcSEcCtD
Vandetanib—Dysphagia—Ursodeoxycholic acid—primary biliary cirrhosis	0.000799	0.00489	CcSEcCtD
Vandetanib—Influenza—Ursodeoxycholic acid—primary biliary cirrhosis	0.000799	0.00489	CcSEcCtD
Vandetanib—Pancreatitis—Chenodeoxycholic acid—primary biliary cirrhosis	0.000783	0.0048	CcSEcCtD
Vandetanib—Pancreatitis—Ursodeoxycholic acid—primary biliary cirrhosis	0.000783	0.0048	CcSEcCtD
Vandetanib—Stomatitis—Colchicine—primary biliary cirrhosis	0.000773	0.00473	CcSEcCtD
Vandetanib—Bronchitis—Chenodeoxycholic acid—primary biliary cirrhosis	0.000768	0.00471	CcSEcCtD
Vandetanib—Bronchitis—Ursodeoxycholic acid—primary biliary cirrhosis	0.000768	0.00471	CcSEcCtD
Vandetanib—Haematuria—Colchicine—primary biliary cirrhosis	0.000756	0.00463	CcSEcCtD
Vandetanib—Dysuria—Ursodeoxycholic acid—primary biliary cirrhosis	0.000747	0.00457	CcSEcCtD
Vandetanib—Dysuria—Chenodeoxycholic acid—primary biliary cirrhosis	0.000747	0.00457	CcSEcCtD
Vandetanib—Upper respiratory tract infection—Ursodeoxycholic acid—primary biliary cirrhosis	0.000742	0.00455	CcSEcCtD
Vandetanib—Upper respiratory tract infection—Chenodeoxycholic acid—primary biliary cirrhosis	0.000742	0.00455	CcSEcCtD
Vandetanib—YES1—liver—primary biliary cirrhosis	0.000741	0.0116	CbGeAlD
Vandetanib—Pollakiuria—Ursodeoxycholic acid—primary biliary cirrhosis	0.000738	0.00452	CcSEcCtD
Vandetanib—Pollakiuria—Chenodeoxycholic acid—primary biliary cirrhosis	0.000738	0.00452	CcSEcCtD
Vandetanib—STK10—liver—primary biliary cirrhosis	0.000734	0.0115	CbGeAlD
Vandetanib—Photosensitivity reaction—Ursodeoxycholic acid—primary biliary cirrhosis	0.000729	0.00447	CcSEcCtD
Vandetanib—Photosensitivity reaction—Chenodeoxycholic acid—primary biliary cirrhosis	0.000729	0.00447	CcSEcCtD
Vandetanib—Weight decreased—Ursodeoxycholic acid—primary biliary cirrhosis	0.000723	0.00443	CcSEcCtD
Vandetanib—Weight decreased—Chenodeoxycholic acid—primary biliary cirrhosis	0.000723	0.00443	CcSEcCtD
Vandetanib—Pneumonia—Chenodeoxycholic acid—primary biliary cirrhosis	0.000716	0.00439	CcSEcCtD
Vandetanib—Pneumonia—Ursodeoxycholic acid—primary biliary cirrhosis	0.000716	0.00439	CcSEcCtD
Vandetanib—SRC—liver—primary biliary cirrhosis	0.000713	0.0111	CbGeAlD
Vandetanib—Infestation NOS—Ursodeoxycholic acid—primary biliary cirrhosis	0.000712	0.00436	CcSEcCtD
Vandetanib—Infestation NOS—Chenodeoxycholic acid—primary biliary cirrhosis	0.000712	0.00436	CcSEcCtD
Vandetanib—Infestation—Ursodeoxycholic acid—primary biliary cirrhosis	0.000712	0.00436	CcSEcCtD
Vandetanib—Infestation—Chenodeoxycholic acid—primary biliary cirrhosis	0.000712	0.00436	CcSEcCtD
Vandetanib—Depression—Chenodeoxycholic acid—primary biliary cirrhosis	0.00071	0.00435	CcSEcCtD
Vandetanib—Depression—Ursodeoxycholic acid—primary biliary cirrhosis	0.00071	0.00435	CcSEcCtD
Vandetanib—Renal failure—Chenodeoxycholic acid—primary biliary cirrhosis	0.0007	0.00429	CcSEcCtD
Vandetanib—Renal failure—Ursodeoxycholic acid—primary biliary cirrhosis	0.0007	0.00429	CcSEcCtD
Vandetanib—Conjunctivitis—Ursodeoxycholic acid—primary biliary cirrhosis	0.000692	0.00424	CcSEcCtD
Vandetanib—Urinary tract infection—Chenodeoxycholic acid—primary biliary cirrhosis	0.000692	0.00424	CcSEcCtD
Vandetanib—Urinary tract infection—Ursodeoxycholic acid—primary biliary cirrhosis	0.000692	0.00424	CcSEcCtD
Vandetanib—Conjunctivitis—Chenodeoxycholic acid—primary biliary cirrhosis	0.000692	0.00424	CcSEcCtD
Vandetanib—Haematuria—Chenodeoxycholic acid—primary biliary cirrhosis	0.000679	0.00416	CcSEcCtD
Vandetanib—Haematuria—Ursodeoxycholic acid—primary biliary cirrhosis	0.000679	0.00416	CcSEcCtD
Vandetanib—Hepatobiliary disease—Ursodeoxycholic acid—primary biliary cirrhosis	0.000674	0.00413	CcSEcCtD
Vandetanib—Hepatobiliary disease—Chenodeoxycholic acid—primary biliary cirrhosis	0.000674	0.00413	CcSEcCtD
Vandetanib—Epistaxis—Ursodeoxycholic acid—primary biliary cirrhosis	0.000672	0.00411	CcSEcCtD
Vandetanib—Epistaxis—Chenodeoxycholic acid—primary biliary cirrhosis	0.000672	0.00411	CcSEcCtD
Vandetanib—Sinusitis—Ursodeoxycholic acid—primary biliary cirrhosis	0.000668	0.00409	CcSEcCtD
Vandetanib—Sinusitis—Chenodeoxycholic acid—primary biliary cirrhosis	0.000668	0.00409	CcSEcCtD
Vandetanib—Eye disorder—Colchicine—primary biliary cirrhosis	0.000665	0.00407	CcSEcCtD
Vandetanib—MAP2K5—liver—primary biliary cirrhosis	0.000656	0.0103	CbGeAlD
Vandetanib—KDR—liver—primary biliary cirrhosis	0.000656	0.0103	CbGeAlD
Vandetanib—Haemoglobin—Chenodeoxycholic acid—primary biliary cirrhosis	0.000643	0.00394	CcSEcCtD
Vandetanib—Haemoglobin—Ursodeoxycholic acid—primary biliary cirrhosis	0.000643	0.00394	CcSEcCtD
Vandetanib—Mediastinal disorder—Colchicine—primary biliary cirrhosis	0.000641	0.00393	CcSEcCtD
Vandetanib—Haemorrhage—Ursodeoxycholic acid—primary biliary cirrhosis	0.000639	0.00392	CcSEcCtD
Vandetanib—Haemorrhage—Chenodeoxycholic acid—primary biliary cirrhosis	0.000639	0.00392	CcSEcCtD
Vandetanib—Urinary tract disorder—Ursodeoxycholic acid—primary biliary cirrhosis	0.000631	0.00387	CcSEcCtD
Vandetanib—Urinary tract disorder—Chenodeoxycholic acid—primary biliary cirrhosis	0.000631	0.00387	CcSEcCtD
Vandetanib—Alopecia—Colchicine—primary biliary cirrhosis	0.000629	0.00385	CcSEcCtD
Vandetanib—Urethral disorder—Ursodeoxycholic acid—primary biliary cirrhosis	0.000627	0.00384	CcSEcCtD
Vandetanib—Urethral disorder—Chenodeoxycholic acid—primary biliary cirrhosis	0.000627	0.00384	CcSEcCtD
Vandetanib—Malnutrition—Colchicine—primary biliary cirrhosis	0.000619	0.00379	CcSEcCtD
Vandetanib—Visual impairment—Chenodeoxycholic acid—primary biliary cirrhosis	0.000616	0.00377	CcSEcCtD
Vandetanib—Visual impairment—Ursodeoxycholic acid—primary biliary cirrhosis	0.000616	0.00377	CcSEcCtD
Vandetanib—Eye disorder—Ursodeoxycholic acid—primary biliary cirrhosis	0.000597	0.00366	CcSEcCtD
Vandetanib—Eye disorder—Chenodeoxycholic acid—primary biliary cirrhosis	0.000597	0.00366	CcSEcCtD
Vandetanib—Muscle spasms—Colchicine—primary biliary cirrhosis	0.000596	0.00365	CcSEcCtD
Vandetanib—Cardiac disorder—Chenodeoxycholic acid—primary biliary cirrhosis	0.000593	0.00363	CcSEcCtD
Vandetanib—Cardiac disorder—Ursodeoxycholic acid—primary biliary cirrhosis	0.000593	0.00363	CcSEcCtD
Vandetanib—Gefitinib—ABCG2—primary biliary cirrhosis	0.000581	0.102	CrCbGaD
Vandetanib—Angiopathy—Chenodeoxycholic acid—primary biliary cirrhosis	0.00058	0.00355	CcSEcCtD
Vandetanib—Angiopathy—Ursodeoxycholic acid—primary biliary cirrhosis	0.00058	0.00355	CcSEcCtD
Vandetanib—Mediastinal disorder—Chenodeoxycholic acid—primary biliary cirrhosis	0.000576	0.00353	CcSEcCtD
Vandetanib—Mediastinal disorder—Ursodeoxycholic acid—primary biliary cirrhosis	0.000576	0.00353	CcSEcCtD
Vandetanib—Arrhythmia—Chenodeoxycholic acid—primary biliary cirrhosis	0.000571	0.0035	CcSEcCtD
Vandetanib—Arrhythmia—Ursodeoxycholic acid—primary biliary cirrhosis	0.000571	0.0035	CcSEcCtD
Vandetanib—PDGFRB—liver—primary biliary cirrhosis	0.000567	0.00887	CbGeAlD
Vandetanib—Alopecia—Ursodeoxycholic acid—primary biliary cirrhosis	0.000565	0.00346	CcSEcCtD
Vandetanib—Alopecia—Chenodeoxycholic acid—primary biliary cirrhosis	0.000565	0.00346	CcSEcCtD
Vandetanib—Malnutrition—Ursodeoxycholic acid—primary biliary cirrhosis	0.000557	0.00341	CcSEcCtD
Vandetanib—Malnutrition—Chenodeoxycholic acid—primary biliary cirrhosis	0.000557	0.00341	CcSEcCtD
Vandetanib—Muscle spasms—Ursodeoxycholic acid—primary biliary cirrhosis	0.000535	0.00328	CcSEcCtD
Vandetanib—Muscle spasms—Chenodeoxycholic acid—primary biliary cirrhosis	0.000535	0.00328	CcSEcCtD
Vandetanib—ORM1—liver—primary biliary cirrhosis	0.000532	0.00832	CbGeAlD
Vandetanib—Arthralgia—Colchicine—primary biliary cirrhosis	0.000527	0.00323	CcSEcCtD
Vandetanib—ABL1—liver—primary biliary cirrhosis	0.000506	0.00791	CbGeAlD
Vandetanib—Nervous system disorder—Colchicine—primary biliary cirrhosis	0.000496	0.00304	CcSEcCtD
Vandetanib—Thrombocytopenia—Colchicine—primary biliary cirrhosis	0.000495	0.00303	CcSEcCtD
Vandetanib—Skin disorder—Colchicine—primary biliary cirrhosis	0.000491	0.00301	CcSEcCtD
Vandetanib—Loss of consciousness—Ursodeoxycholic acid—primary biliary cirrhosis	0.000489	0.003	CcSEcCtD
Vandetanib—Loss of consciousness—Chenodeoxycholic acid—primary biliary cirrhosis	0.000489	0.003	CcSEcCtD
Vandetanib—Cough—Chenodeoxycholic acid—primary biliary cirrhosis	0.000486	0.00297	CcSEcCtD
Vandetanib—Cough—Ursodeoxycholic acid—primary biliary cirrhosis	0.000486	0.00297	CcSEcCtD
Vandetanib—Convulsion—Ursodeoxycholic acid—primary biliary cirrhosis	0.000482	0.00295	CcSEcCtD
Vandetanib—Convulsion—Chenodeoxycholic acid—primary biliary cirrhosis	0.000482	0.00295	CcSEcCtD
Vandetanib—Hypertension—Chenodeoxycholic acid—primary biliary cirrhosis	0.00048	0.00294	CcSEcCtD
Vandetanib—Hypertension—Ursodeoxycholic acid—primary biliary cirrhosis	0.00048	0.00294	CcSEcCtD
Vandetanib—Arthralgia—Chenodeoxycholic acid—primary biliary cirrhosis	0.000474	0.0029	CcSEcCtD
Vandetanib—Chest pain—Ursodeoxycholic acid—primary biliary cirrhosis	0.000474	0.0029	CcSEcCtD
Vandetanib—Chest pain—Chenodeoxycholic acid—primary biliary cirrhosis	0.000474	0.0029	CcSEcCtD
Vandetanib—Arthralgia—Ursodeoxycholic acid—primary biliary cirrhosis	0.000474	0.0029	CcSEcCtD
Vandetanib—Unspecified disorder of skin and subcutaneous tissue—Ursodeoxycholic acid—primary biliary cirrhosis	0.000471	0.00288	CcSEcCtD
Vandetanib—Unspecified disorder of skin and subcutaneous tissue—Chenodeoxycholic acid—primary biliary cirrhosis	0.000471	0.00288	CcSEcCtD
Vandetanib—ALB—liver—primary biliary cirrhosis	0.000467	0.0073	CbGeAlD
Vandetanib—Dry mouth—Chenodeoxycholic acid—primary biliary cirrhosis	0.000463	0.00284	CcSEcCtD
Vandetanib—Dry mouth—Ursodeoxycholic acid—primary biliary cirrhosis	0.000463	0.00284	CcSEcCtD
Vandetanib—Musculoskeletal discomfort—Colchicine—primary biliary cirrhosis	0.000461	0.00282	CcSEcCtD
Vandetanib—Oedema—Ursodeoxycholic acid—primary biliary cirrhosis	0.000454	0.00278	CcSEcCtD
Vandetanib—Oedema—Chenodeoxycholic acid—primary biliary cirrhosis	0.000454	0.00278	CcSEcCtD
Vandetanib—Infection—Chenodeoxycholic acid—primary biliary cirrhosis	0.000451	0.00276	CcSEcCtD
Vandetanib—Infection—Ursodeoxycholic acid—primary biliary cirrhosis	0.000451	0.00276	CcSEcCtD
Vandetanib—Nervous system disorder—Ursodeoxycholic acid—primary biliary cirrhosis	0.000445	0.00273	CcSEcCtD
Vandetanib—Nervous system disorder—Chenodeoxycholic acid—primary biliary cirrhosis	0.000445	0.00273	CcSEcCtD
Vandetanib—Thrombocytopenia—Chenodeoxycholic acid—primary biliary cirrhosis	0.000445	0.00272	CcSEcCtD
Vandetanib—Thrombocytopenia—Ursodeoxycholic acid—primary biliary cirrhosis	0.000445	0.00272	CcSEcCtD
Vandetanib—Skin disorder—Ursodeoxycholic acid—primary biliary cirrhosis	0.000441	0.0027	CcSEcCtD
Vandetanib—Skin disorder—Chenodeoxycholic acid—primary biliary cirrhosis	0.000441	0.0027	CcSEcCtD
Vandetanib—Decreased appetite—Colchicine—primary biliary cirrhosis	0.000439	0.00269	CcSEcCtD
Vandetanib—Gastrointestinal disorder—Colchicine—primary biliary cirrhosis	0.000436	0.00267	CcSEcCtD
Vandetanib—Fatigue—Colchicine—primary biliary cirrhosis	0.000436	0.00267	CcSEcCtD
Vandetanib—Musculoskeletal discomfort—Ursodeoxycholic acid—primary biliary cirrhosis	0.000414	0.00253	CcSEcCtD
Vandetanib—Musculoskeletal discomfort—Chenodeoxycholic acid—primary biliary cirrhosis	0.000414	0.00253	CcSEcCtD
Vandetanib—Gastrointestinal pain—Colchicine—primary biliary cirrhosis	0.000413	0.00253	CcSEcCtD
Vandetanib—Insomnia—Ursodeoxycholic acid—primary biliary cirrhosis	0.000411	0.00252	CcSEcCtD
Vandetanib—Insomnia—Chenodeoxycholic acid—primary biliary cirrhosis	0.000411	0.00252	CcSEcCtD
Vandetanib—Paraesthesia—Ursodeoxycholic acid—primary biliary cirrhosis	0.000408	0.0025	CcSEcCtD
Vandetanib—Paraesthesia—Chenodeoxycholic acid—primary biliary cirrhosis	0.000408	0.0025	CcSEcCtD
Vandetanib—Dyspnoea—Ursodeoxycholic acid—primary biliary cirrhosis	0.000405	0.00248	CcSEcCtD
Vandetanib—Dyspnoea—Chenodeoxycholic acid—primary biliary cirrhosis	0.000405	0.00248	CcSEcCtD
Vandetanib—Erlotinib—ALB—primary biliary cirrhosis	0.000405	0.0708	CrCbGaD
Vandetanib—Dyspepsia—Chenodeoxycholic acid—primary biliary cirrhosis	0.0004	0.00245	CcSEcCtD
Vandetanib—Dyspepsia—Ursodeoxycholic acid—primary biliary cirrhosis	0.0004	0.00245	CcSEcCtD
Vandetanib—Abdominal pain—Colchicine—primary biliary cirrhosis	0.0004	0.00245	CcSEcCtD
Vandetanib—Decreased appetite—Ursodeoxycholic acid—primary biliary cirrhosis	0.000395	0.00242	CcSEcCtD
Vandetanib—Decreased appetite—Chenodeoxycholic acid—primary biliary cirrhosis	0.000395	0.00242	CcSEcCtD
Vandetanib—Gastrointestinal disorder—Chenodeoxycholic acid—primary biliary cirrhosis	0.000392	0.0024	CcSEcCtD
Vandetanib—Gastrointestinal disorder—Ursodeoxycholic acid—primary biliary cirrhosis	0.000392	0.0024	CcSEcCtD
Vandetanib—Fatigue—Chenodeoxycholic acid—primary biliary cirrhosis	0.000392	0.0024	CcSEcCtD
Vandetanib—Fatigue—Ursodeoxycholic acid—primary biliary cirrhosis	0.000392	0.0024	CcSEcCtD
Vandetanib—Pain—Ursodeoxycholic acid—primary biliary cirrhosis	0.000388	0.00238	CcSEcCtD
Vandetanib—Pain—Chenodeoxycholic acid—primary biliary cirrhosis	0.000388	0.00238	CcSEcCtD
Vandetanib—Constipation—Ursodeoxycholic acid—primary biliary cirrhosis	0.000388	0.00238	CcSEcCtD
Vandetanib—Constipation—Chenodeoxycholic acid—primary biliary cirrhosis	0.000388	0.00238	CcSEcCtD
Vandetanib—ABCC1—liver—primary biliary cirrhosis	0.000385	0.00602	CbGeAlD
Vandetanib—Gastrointestinal pain—Ursodeoxycholic acid—primary biliary cirrhosis	0.000371	0.00227	CcSEcCtD
Vandetanib—Gastrointestinal pain—Chenodeoxycholic acid—primary biliary cirrhosis	0.000371	0.00227	CcSEcCtD
Vandetanib—Asthenia—Colchicine—primary biliary cirrhosis	0.000363	0.00222	CcSEcCtD
Vandetanib—Body temperature increased—Ursodeoxycholic acid—primary biliary cirrhosis	0.000359	0.0022	CcSEcCtD
Vandetanib—Abdominal pain—Chenodeoxycholic acid—primary biliary cirrhosis	0.000359	0.0022	CcSEcCtD
Vandetanib—Body temperature increased—Chenodeoxycholic acid—primary biliary cirrhosis	0.000359	0.0022	CcSEcCtD
Vandetanib—Abdominal pain—Ursodeoxycholic acid—primary biliary cirrhosis	0.000359	0.0022	CcSEcCtD
Vandetanib—Diarrhoea—Colchicine—primary biliary cirrhosis	0.000346	0.00212	CcSEcCtD
Vandetanib—Asthenia—Chenodeoxycholic acid—primary biliary cirrhosis	0.000326	0.002	CcSEcCtD
Vandetanib—Asthenia—Ursodeoxycholic acid—primary biliary cirrhosis	0.000326	0.002	CcSEcCtD
Vandetanib—Vomiting—Colchicine—primary biliary cirrhosis	0.000321	0.00197	CcSEcCtD
Vandetanib—Pruritus—Chenodeoxycholic acid—primary biliary cirrhosis	0.000321	0.00197	CcSEcCtD
Vandetanib—Pruritus—Ursodeoxycholic acid—primary biliary cirrhosis	0.000321	0.00197	CcSEcCtD
Vandetanib—ABCG2—liver—primary biliary cirrhosis	0.000319	0.00499	CbGeAlD
Vandetanib—Rash—Colchicine—primary biliary cirrhosis	0.000319	0.00195	CcSEcCtD
Vandetanib—Dermatitis—Colchicine—primary biliary cirrhosis	0.000318	0.00195	CcSEcCtD
Vandetanib—Headache—Colchicine—primary biliary cirrhosis	0.000317	0.00194	CcSEcCtD
Vandetanib—Diarrhoea—Chenodeoxycholic acid—primary biliary cirrhosis	0.000311	0.0019	CcSEcCtD
Vandetanib—Diarrhoea—Ursodeoxycholic acid—primary biliary cirrhosis	0.000311	0.0019	CcSEcCtD
Vandetanib—Dizziness—Ursodeoxycholic acid—primary biliary cirrhosis	0.0003	0.00184	CcSEcCtD
Vandetanib—Dizziness—Chenodeoxycholic acid—primary biliary cirrhosis	0.0003	0.00184	CcSEcCtD
Vandetanib—Nausea—Colchicine—primary biliary cirrhosis	0.0003	0.00184	CcSEcCtD
Vandetanib—Vomiting—Ursodeoxycholic acid—primary biliary cirrhosis	0.000289	0.00177	CcSEcCtD
Vandetanib—Vomiting—Chenodeoxycholic acid—primary biliary cirrhosis	0.000289	0.00177	CcSEcCtD
Vandetanib—Rash—Ursodeoxycholic acid—primary biliary cirrhosis	0.000286	0.00175	CcSEcCtD
Vandetanib—Rash—Chenodeoxycholic acid—primary biliary cirrhosis	0.000286	0.00175	CcSEcCtD
Vandetanib—Dermatitis—Chenodeoxycholic acid—primary biliary cirrhosis	0.000286	0.00175	CcSEcCtD
Vandetanib—Dermatitis—Ursodeoxycholic acid—primary biliary cirrhosis	0.000286	0.00175	CcSEcCtD
Vandetanib—Headache—Chenodeoxycholic acid—primary biliary cirrhosis	0.000285	0.00174	CcSEcCtD
Vandetanib—Headache—Ursodeoxycholic acid—primary biliary cirrhosis	0.000285	0.00174	CcSEcCtD
Vandetanib—Nausea—Chenodeoxycholic acid—primary biliary cirrhosis	0.00027	0.00165	CcSEcCtD
Vandetanib—Nausea—Ursodeoxycholic acid—primary biliary cirrhosis	0.00027	0.00165	CcSEcCtD
Vandetanib—Gefitinib—ALB—primary biliary cirrhosis	0.000253	0.0443	CrCbGaD
Vandetanib—CYP3A4—liver—primary biliary cirrhosis	0.000222	0.00347	CbGeAlD
Vandetanib—ABCC1—Metabolism—CTGF—primary biliary cirrhosis	1.05e-05	5.89e-05	CbGpPWpGaD
Vandetanib—LCK—Immune System—TAB1—primary biliary cirrhosis	1.05e-05	5.88e-05	CbGpPWpGaD
Vandetanib—FYN—Immune System—CD40LG—primary biliary cirrhosis	1.05e-05	5.87e-05	CbGpPWpGaD
Vandetanib—FLT4—Signaling Pathways—NFKB1—primary biliary cirrhosis	1.05e-05	5.87e-05	CbGpPWpGaD
Vandetanib—ABCC1—Metabolism—GOT2—primary biliary cirrhosis	1.04e-05	5.84e-05	CbGpPWpGaD
Vandetanib—SRC—Axon guidance—MMP9—primary biliary cirrhosis	1.04e-05	5.83e-05	CbGpPWpGaD
Vandetanib—SRC—Signaling Pathways—ELMO1—primary biliary cirrhosis	1.04e-05	5.79e-05	CbGpPWpGaD
Vandetanib—KDR—Signaling Pathways—RPS6KB1—primary biliary cirrhosis	1.04e-05	5.79e-05	CbGpPWpGaD
Vandetanib—FMO3—Metabolism—ALB—primary biliary cirrhosis	1.03e-05	5.78e-05	CbGpPWpGaD
Vandetanib—LYN—Developmental Biology—MMP9—primary biliary cirrhosis	1.03e-05	5.73e-05	CbGpPWpGaD
Vandetanib—ERBB3—Signaling Pathways—RPS6KB1—primary biliary cirrhosis	1.02e-05	5.73e-05	CbGpPWpGaD
Vandetanib—ABCC1—Transmembrane transport of small molecules—ALB—primary biliary cirrhosis	1.02e-05	5.72e-05	CbGpPWpGaD
Vandetanib—ERBB3—Immune System—TYK2—primary biliary cirrhosis	1.02e-05	5.72e-05	CbGpPWpGaD
Vandetanib—ABL1—Developmental Biology—MMP9—primary biliary cirrhosis	1.02e-05	5.71e-05	CbGpPWpGaD
Vandetanib—VEGFA—Signaling Pathways—MMP3—primary biliary cirrhosis	1.02e-05	5.69e-05	CbGpPWpGaD
Vandetanib—EGFR—Disease—GOT1—primary biliary cirrhosis	1.01e-05	5.67e-05	CbGpPWpGaD
Vandetanib—LYN—Developmental Biology—NFKB1—primary biliary cirrhosis	1.01e-05	5.67e-05	CbGpPWpGaD
Vandetanib—ABL1—Developmental Biology—NFKB1—primary biliary cirrhosis	1.01e-05	5.65e-05	CbGpPWpGaD
Vandetanib—FYN—Developmental Biology—MMP9—primary biliary cirrhosis	1.01e-05	5.64e-05	CbGpPWpGaD
Vandetanib—RIPK2—Signaling Pathways—HIF1A—primary biliary cirrhosis	1.01e-05	5.63e-05	CbGpPWpGaD
Vandetanib—RIPK2—Signaling Pathways—AGT—primary biliary cirrhosis	1e-05	5.61e-05	CbGpPWpGaD
Vandetanib—SRC—Disease—GOT2—primary biliary cirrhosis	1e-05	5.61e-05	CbGpPWpGaD
Vandetanib—IRAK4—Immune System—NFKB1—primary biliary cirrhosis	1e-05	5.59e-05	CbGpPWpGaD
Vandetanib—FYN—Developmental Biology—NFKB1—primary biliary cirrhosis	9.99e-06	5.58e-05	CbGpPWpGaD
Vandetanib—EGFR—Signaling by GPCR—CCL5—primary biliary cirrhosis	9.97e-06	5.57e-05	CbGpPWpGaD
Vandetanib—SRC—Immune System—CTLA4—primary biliary cirrhosis	9.95e-06	5.56e-05	CbGpPWpGaD
Vandetanib—SRC—Developmental Biology—MMP2—primary biliary cirrhosis	9.9e-06	5.53e-05	CbGpPWpGaD
Vandetanib—SRC—Innate Immune System—CD80—primary biliary cirrhosis	9.88e-06	5.53e-05	CbGpPWpGaD
Vandetanib—YES1—Signaling Pathways—MMP3—primary biliary cirrhosis	9.84e-06	5.5e-05	CbGpPWpGaD
Vandetanib—ALB—Metabolism of lipids and lipoproteins—PPARGC1A—primary biliary cirrhosis	9.78e-06	5.47e-05	CbGpPWpGaD
Vandetanib—EGFR—Innate Immune System—TYK2—primary biliary cirrhosis	9.78e-06	5.47e-05	CbGpPWpGaD
Vandetanib—LCK—Disease—GOT1—primary biliary cirrhosis	9.78e-06	5.47e-05	CbGpPWpGaD
Vandetanib—VEGFA—Signaling Pathways—CCL5—primary biliary cirrhosis	9.61e-06	5.37e-05	CbGpPWpGaD
Vandetanib—SRC—Hemostasis—ALB—primary biliary cirrhosis	9.51e-06	5.32e-05	CbGpPWpGaD
Vandetanib—SRC—Immune System—CD79A—primary biliary cirrhosis	9.49e-06	5.31e-05	CbGpPWpGaD
Vandetanib—SRC—Adaptive Immune System—CD80—primary biliary cirrhosis	9.49e-06	5.31e-05	CbGpPWpGaD
Vandetanib—SRC—Developmental Biology—TYK2—primary biliary cirrhosis	9.45e-06	5.28e-05	CbGpPWpGaD
Vandetanib—ERBB3—Disease—TYK2—primary biliary cirrhosis	9.45e-06	5.28e-05	CbGpPWpGaD
Vandetanib—LCK—Innate Immune System—TYK2—primary biliary cirrhosis	9.43e-06	5.27e-05	CbGpPWpGaD
Vandetanib—SRC—Immune System—TAB1—primary biliary cirrhosis	9.32e-06	5.21e-05	CbGpPWpGaD
Vandetanib—VEGFA—Signaling Pathways—RPS6KB1—primary biliary cirrhosis	9.31e-06	5.21e-05	CbGpPWpGaD
Vandetanib—YES1—Signaling Pathways—CCL5—primary biliary cirrhosis	9.28e-06	5.19e-05	CbGpPWpGaD
Vandetanib—ABCG2—Metabolism—CTGF—primary biliary cirrhosis	9.27e-06	5.18e-05	CbGpPWpGaD
Vandetanib—MAP2K5—Signaling Pathways—HIF1A—primary biliary cirrhosis	9.21e-06	5.15e-05	CbGpPWpGaD
Vandetanib—ABCG2—Metabolism—GOT2—primary biliary cirrhosis	9.19e-06	5.14e-05	CbGpPWpGaD
Vandetanib—MAP2K5—Signaling Pathways—AGT—primary biliary cirrhosis	9.18e-06	5.13e-05	CbGpPWpGaD
Vandetanib—PDGFRB—Innate Immune System—NFKB1—primary biliary cirrhosis	9.15e-06	5.12e-05	CbGpPWpGaD
Vandetanib—EGFR—Immune System—CD40LG—primary biliary cirrhosis	9.07e-06	5.07e-05	CbGpPWpGaD
Vandetanib—RIPK2—Immune System—NFKB1—primary biliary cirrhosis	9.04e-06	5.06e-05	CbGpPWpGaD
Vandetanib—ABCC1—Metabolism—GOT1—primary biliary cirrhosis	9.01e-06	5.04e-05	CbGpPWpGaD
Vandetanib—ABCC1—Metabolism—GGT1—primary biliary cirrhosis	9.01e-06	5.04e-05	CbGpPWpGaD
Vandetanib—ABCG2—Transmembrane transport of small molecules—ALB—primary biliary cirrhosis	9.01e-06	5.04e-05	CbGpPWpGaD
Vandetanib—YES1—Signaling Pathways—RPS6KB1—primary biliary cirrhosis	9e-06	5.03e-05	CbGpPWpGaD
Vandetanib—YES1—Immune System—TYK2—primary biliary cirrhosis	8.98e-06	5.02e-05	CbGpPWpGaD
Vandetanib—KDR—Signaling Pathways—HIF1A—primary biliary cirrhosis	8.98e-06	5.02e-05	CbGpPWpGaD
Vandetanib—LYN—Innate Immune System—NFKB1—primary biliary cirrhosis	8.96e-06	5.01e-05	CbGpPWpGaD
Vandetanib—KDR—Signaling Pathways—AGT—primary biliary cirrhosis	8.94e-06	5e-05	CbGpPWpGaD
Vandetanib—ABL1—Innate Immune System—NFKB1—primary biliary cirrhosis	8.92e-06	4.99e-05	CbGpPWpGaD
Vandetanib—RIPK2—Signaling Pathways—CD80—primary biliary cirrhosis	8.89e-06	4.97e-05	CbGpPWpGaD
Vandetanib—ERBB3—Signaling Pathways—HIF1A—primary biliary cirrhosis	8.88e-06	4.96e-05	CbGpPWpGaD
Vandetanib—ERBB3—Signaling Pathways—AGT—primary biliary cirrhosis	8.85e-06	4.95e-05	CbGpPWpGaD
Vandetanib—FYN—Innate Immune System—NFKB1—primary biliary cirrhosis	8.82e-06	4.93e-05	CbGpPWpGaD
Vandetanib—MKNK1—Signaling Pathways—MMP9—primary biliary cirrhosis	8.79e-06	4.92e-05	CbGpPWpGaD
Vandetanib—PDGFRB—Adaptive Immune System—NFKB1—primary biliary cirrhosis	8.79e-06	4.91e-05	CbGpPWpGaD
Vandetanib—LCK—Immune System—CD40LG—primary biliary cirrhosis	8.74e-06	4.89e-05	CbGpPWpGaD
Vandetanib—EGFR—Developmental Biology—MMP9—primary biliary cirrhosis	8.72e-06	4.88e-05	CbGpPWpGaD
Vandetanib—BLK—Immune System—NFKB1—primary biliary cirrhosis	8.7e-06	4.86e-05	CbGpPWpGaD
Vandetanib—MKNK1—Signaling Pathways—NFKB1—primary biliary cirrhosis	8.7e-06	4.86e-05	CbGpPWpGaD
Vandetanib—FGR—Immune System—NFKB1—primary biliary cirrhosis	8.67e-06	4.85e-05	CbGpPWpGaD
Vandetanib—SRC—Disease—GOT1—primary biliary cirrhosis	8.66e-06	4.84e-05	CbGpPWpGaD
Vandetanib—EGFR—Developmental Biology—NFKB1—primary biliary cirrhosis	8.63e-06	4.82e-05	CbGpPWpGaD
Vandetanib—LYN—Adaptive Immune System—NFKB1—primary biliary cirrhosis	8.6e-06	4.81e-05	CbGpPWpGaD
Vandetanib—PDGFRB—Disease—HIF1A—primary biliary cirrhosis	8.48e-06	4.74e-05	CbGpPWpGaD
Vandetanib—FYN—Adaptive Immune System—NFKB1—primary biliary cirrhosis	8.47e-06	4.74e-05	CbGpPWpGaD
Vandetanib—SRC—Innate Immune System—TYK2—primary biliary cirrhosis	8.34e-06	4.66e-05	CbGpPWpGaD
Vandetanib—EGFR—Signaling by GPCR—AGT—primary biliary cirrhosis	8.34e-06	4.66e-05	CbGpPWpGaD
Vandetanib—PDGFRB—Signaling Pathways—CXCL10—primary biliary cirrhosis	8.21e-06	4.59e-05	CbGpPWpGaD
Vandetanib—FYN—Disease—HIF1A—primary biliary cirrhosis	8.17e-06	4.57e-05	CbGpPWpGaD
Vandetanib—MAP2K5—Signaling Pathways—CD80—primary biliary cirrhosis	8.13e-06	4.55e-05	CbGpPWpGaD
Vandetanib—PDGFRB—Immune System—CD80—primary biliary cirrhosis	8.1e-06	4.53e-05	CbGpPWpGaD
Vandetanib—VEGFA—Signaling Pathways—HIF1A—primary biliary cirrhosis	8.07e-06	4.51e-05	CbGpPWpGaD
Vandetanib—LYN—Signaling Pathways—CXCL10—primary biliary cirrhosis	8.04e-06	4.5e-05	CbGpPWpGaD
Vandetanib—VEGFA—Signaling Pathways—AGT—primary biliary cirrhosis	8.04e-06	4.49e-05	CbGpPWpGaD
Vandetanib—ABCC1—Metabolism—PPARGC1A—primary biliary cirrhosis	8.02e-06	4.49e-05	CbGpPWpGaD
Vandetanib—ERBB3—Immune System—NFKB1—primary biliary cirrhosis	7.97e-06	4.46e-05	CbGpPWpGaD
Vandetanib—LYN—Immune System—CD80—primary biliary cirrhosis	7.93e-06	4.44e-05	CbGpPWpGaD
Vandetanib—ABCG2—Metabolism—GGT1—primary biliary cirrhosis	7.93e-06	4.43e-05	CbGpPWpGaD
Vandetanib—ABCG2—Metabolism—GOT1—primary biliary cirrhosis	7.93e-06	4.43e-05	CbGpPWpGaD
Vandetanib—KDR—Signaling Pathways—CD80—primary biliary cirrhosis	7.92e-06	4.43e-05	CbGpPWpGaD
Vandetanib—FYN—Signaling Pathways—CXCL10—primary biliary cirrhosis	7.92e-06	4.43e-05	CbGpPWpGaD
Vandetanib—ABL1—Immune System—CD80—primary biliary cirrhosis	7.9e-06	4.41e-05	CbGpPWpGaD
Vandetanib—ERBB3—Signaling Pathways—CD80—primary biliary cirrhosis	7.84e-06	4.38e-05	CbGpPWpGaD
Vandetanib—FYN—Immune System—CD80—primary biliary cirrhosis	7.81e-06	4.37e-05	CbGpPWpGaD
Vandetanib—YES1—Signaling Pathways—HIF1A—primary biliary cirrhosis	7.79e-06	4.36e-05	CbGpPWpGaD
Vandetanib—YES1—Signaling Pathways—AGT—primary biliary cirrhosis	7.77e-06	4.34e-05	CbGpPWpGaD
Vandetanib—SRC—Immune System—CD40LG—primary biliary cirrhosis	7.74e-06	4.33e-05	CbGpPWpGaD
Vandetanib—PDGFRB—Disease—NOS2—primary biliary cirrhosis	7.71e-06	4.31e-05	CbGpPWpGaD
Vandetanib—CYP3A4—Metabolism—OGDH—primary biliary cirrhosis	7.69e-06	4.3e-05	CbGpPWpGaD
Vandetanib—ALB—Hemostasis—NOS2—primary biliary cirrhosis	7.64e-06	4.27e-05	CbGpPWpGaD
Vandetanib—EGFR—Innate Immune System—NFKB1—primary biliary cirrhosis	7.62e-06	4.26e-05	CbGpPWpGaD
Vandetanib—ALB—Metabolism of lipids and lipoproteins—AGT—primary biliary cirrhosis	7.62e-06	4.26e-05	CbGpPWpGaD
Vandetanib—RIPK2—Signaling Pathways—TYK2—primary biliary cirrhosis	7.5e-06	4.2e-05	CbGpPWpGaD
Vandetanib—PDGFRB—Signaling Pathways—MMP3—primary biliary cirrhosis	7.49e-06	4.19e-05	CbGpPWpGaD
Vandetanib—ABCC1—Disease—HIF1A—primary biliary cirrhosis	7.49e-06	4.19e-05	CbGpPWpGaD
Vandetanib—PDGFRB—Disease—CD80—primary biliary cirrhosis	7.48e-06	4.18e-05	CbGpPWpGaD
Vandetanib—SRC—Developmental Biology—MMP9—primary biliary cirrhosis	7.44e-06	4.16e-05	CbGpPWpGaD
Vandetanib—FYN—Disease—NOS2—primary biliary cirrhosis	7.43e-06	4.16e-05	CbGpPWpGaD
Vandetanib—SRC—Developmental Biology—NFKB1—primary biliary cirrhosis	7.36e-06	4.12e-05	CbGpPWpGaD
Vandetanib—LCK—Innate Immune System—NFKB1—primary biliary cirrhosis	7.34e-06	4.11e-05	CbGpPWpGaD
Vandetanib—LYN—Signaling Pathways—MMP3—primary biliary cirrhosis	7.33e-06	4.1e-05	CbGpPWpGaD
Vandetanib—EGFR—Adaptive Immune System—NFKB1—primary biliary cirrhosis	7.32e-06	4.09e-05	CbGpPWpGaD
Vandetanib—FYN—Signaling Pathways—MMP3—primary biliary cirrhosis	7.22e-06	4.04e-05	CbGpPWpGaD
Vandetanib—FYN—Disease—CD80—primary biliary cirrhosis	7.21e-06	4.03e-05	CbGpPWpGaD
Vandetanib—ALB—Metabolism—NUP210—primary biliary cirrhosis	7.17e-06	4.01e-05	CbGpPWpGaD
Vandetanib—VEGFA—Signaling Pathways—CD80—primary biliary cirrhosis	7.12e-06	3.98e-05	CbGpPWpGaD
Vandetanib—PDGFRB—Signaling Pathways—CCL5—primary biliary cirrhosis	7.07e-06	3.95e-05	CbGpPWpGaD
Vandetanib—ABCG2—Metabolism—PPARGC1A—primary biliary cirrhosis	7.06e-06	3.95e-05	CbGpPWpGaD
Vandetanib—EGFR—Disease—HIF1A—primary biliary cirrhosis	7.06e-06	3.95e-05	CbGpPWpGaD
Vandetanib—LCK—Adaptive Immune System—NFKB1—primary biliary cirrhosis	7.05e-06	3.94e-05	CbGpPWpGaD
Vandetanib—YES1—Immune System—NFKB1—primary biliary cirrhosis	7e-06	3.91e-05	CbGpPWpGaD
Vandetanib—LYN—Signaling Pathways—CCL5—primary biliary cirrhosis	6.92e-06	3.87e-05	CbGpPWpGaD
Vandetanib—YES1—Signaling Pathways—CD80—primary biliary cirrhosis	6.88e-06	3.85e-05	CbGpPWpGaD
Vandetanib—MAP2K5—Signaling Pathways—TYK2—primary biliary cirrhosis	6.86e-06	3.84e-05	CbGpPWpGaD
Vandetanib—CYP3A4—Metabolism—PDHX—primary biliary cirrhosis	6.85e-06	3.83e-05	CbGpPWpGaD
Vandetanib—PDGFRB—Signaling Pathways—RPS6KB1—primary biliary cirrhosis	6.85e-06	3.83e-05	CbGpPWpGaD
Vandetanib—PDGFRB—Immune System—TYK2—primary biliary cirrhosis	6.84e-06	3.82e-05	CbGpPWpGaD
Vandetanib—EGFR—Signaling Pathways—CXCL10—primary biliary cirrhosis	6.84e-06	3.82e-05	CbGpPWpGaD
Vandetanib—FYN—Signaling Pathways—CCL5—primary biliary cirrhosis	6.81e-06	3.81e-05	CbGpPWpGaD
Vandetanib—ABCC1—Disease—NOS2—primary biliary cirrhosis	6.81e-06	3.81e-05	CbGpPWpGaD
Vandetanib—LCK—Disease—HIF1A—primary biliary cirrhosis	6.8e-06	3.8e-05	CbGpPWpGaD
Vandetanib—EGFR—Immune System—CD80—primary biliary cirrhosis	6.75e-06	3.77e-05	CbGpPWpGaD
Vandetanib—LYN—Signaling Pathways—RPS6KB1—primary biliary cirrhosis	6.71e-06	3.75e-05	CbGpPWpGaD
Vandetanib—LYN—Immune System—TYK2—primary biliary cirrhosis	6.7e-06	3.74e-05	CbGpPWpGaD
Vandetanib—KDR—Signaling Pathways—TYK2—primary biliary cirrhosis	6.69e-06	3.74e-05	CbGpPWpGaD
Vandetanib—ALB—Metabolism—ABCG2—primary biliary cirrhosis	6.67e-06	3.73e-05	CbGpPWpGaD
Vandetanib—ABL1—Immune System—TYK2—primary biliary cirrhosis	6.67e-06	3.73e-05	CbGpPWpGaD
Vandetanib—ERBB3—Signaling Pathways—TYK2—primary biliary cirrhosis	6.62e-06	3.7e-05	CbGpPWpGaD
Vandetanib—ABCC1—Disease—CD80—primary biliary cirrhosis	6.61e-06	3.7e-05	CbGpPWpGaD
Vandetanib—FYN—Signaling Pathways—RPS6KB1—primary biliary cirrhosis	6.6e-06	3.69e-05	CbGpPWpGaD
Vandetanib—FYN—Immune System—TYK2—primary biliary cirrhosis	6.59e-06	3.69e-05	CbGpPWpGaD
Vandetanib—LCK—Signaling Pathways—CXCL10—primary biliary cirrhosis	6.59e-06	3.68e-05	CbGpPWpGaD
Vandetanib—LCK—Immune System—CD80—primary biliary cirrhosis	6.5e-06	3.64e-05	CbGpPWpGaD
Vandetanib—SRC—Innate Immune System—NFKB1—primary biliary cirrhosis	6.5e-06	3.63e-05	CbGpPWpGaD
Vandetanib—CYP3A4—Metabolism—DLAT—primary biliary cirrhosis	6.44e-06	3.6e-05	CbGpPWpGaD
Vandetanib—CYP3A4—Metabolism—ABCB4—primary biliary cirrhosis	6.44e-06	3.6e-05	CbGpPWpGaD
Vandetanib—EGFR—Disease—NOS2—primary biliary cirrhosis	6.42e-06	3.59e-05	CbGpPWpGaD
Vandetanib—PDGFRB—Disease—TYK2—primary biliary cirrhosis	6.32e-06	3.53e-05	CbGpPWpGaD
Vandetanib—ABCC1—Metabolism—AGT—primary biliary cirrhosis	6.25e-06	3.49e-05	CbGpPWpGaD
Vandetanib—SRC—Adaptive Immune System—NFKB1—primary biliary cirrhosis	6.24e-06	3.49e-05	CbGpPWpGaD
Vandetanib—EGFR—Signaling Pathways—MMP3—primary biliary cirrhosis	6.24e-06	3.49e-05	CbGpPWpGaD
Vandetanib—EGFR—Signaling by GPCR—TYK2—primary biliary cirrhosis	6.23e-06	3.49e-05	CbGpPWpGaD
Vandetanib—EGFR—Disease—CD80—primary biliary cirrhosis	6.23e-06	3.48e-05	CbGpPWpGaD
Vandetanib—LCK—Disease—NOS2—primary biliary cirrhosis	6.19e-06	3.46e-05	CbGpPWpGaD
Vandetanib—FYN—Disease—TYK2—primary biliary cirrhosis	6.09e-06	3.4e-05	CbGpPWpGaD
Vandetanib—SRC—Disease—HIF1A—primary biliary cirrhosis	6.02e-06	3.37e-05	CbGpPWpGaD
Vandetanib—VEGFA—Signaling Pathways—TYK2—primary biliary cirrhosis	6.01e-06	3.36e-05	CbGpPWpGaD
Vandetanib—LCK—Signaling Pathways—MMP3—primary biliary cirrhosis	6.01e-06	3.36e-05	CbGpPWpGaD
Vandetanib—LCK—Disease—CD80—primary biliary cirrhosis	6e-06	3.36e-05	CbGpPWpGaD
Vandetanib—PDGFRB—Signaling Pathways—HIF1A—primary biliary cirrhosis	5.94e-06	3.32e-05	CbGpPWpGaD
Vandetanib—PDGFRB—Signaling Pathways—AGT—primary biliary cirrhosis	5.91e-06	3.31e-05	CbGpPWpGaD
Vandetanib—RIPK2—Signaling Pathways—MMP9—primary biliary cirrhosis	5.91e-06	3.3e-05	CbGpPWpGaD
Vandetanib—EGFR—Signaling Pathways—CCL5—primary biliary cirrhosis	5.89e-06	3.29e-05	CbGpPWpGaD
Vandetanib—RIPK2—Signaling Pathways—NFKB1—primary biliary cirrhosis	5.85e-06	3.27e-05	CbGpPWpGaD
Vandetanib—SRC—Signaling Pathways—CXCL10—primary biliary cirrhosis	5.83e-06	3.26e-05	CbGpPWpGaD
Vandetanib—LYN—Signaling Pathways—HIF1A—primary biliary cirrhosis	5.81e-06	3.25e-05	CbGpPWpGaD
Vandetanib—YES1—Signaling Pathways—TYK2—primary biliary cirrhosis	5.81e-06	3.25e-05	CbGpPWpGaD
Vandetanib—LYN—Signaling Pathways—AGT—primary biliary cirrhosis	5.79e-06	3.24e-05	CbGpPWpGaD
Vandetanib—SRC—Immune System—CD80—primary biliary cirrhosis	5.76e-06	3.22e-05	CbGpPWpGaD
Vandetanib—ALB—Metabolism—CTGF—primary biliary cirrhosis	5.72e-06	3.2e-05	CbGpPWpGaD
Vandetanib—FYN—Signaling Pathways—HIF1A—primary biliary cirrhosis	5.72e-06	3.2e-05	CbGpPWpGaD
Vandetanib—EGFR—Signaling Pathways—RPS6KB1—primary biliary cirrhosis	5.71e-06	3.19e-05	CbGpPWpGaD
Vandetanib—FYN—Signaling Pathways—AGT—primary biliary cirrhosis	5.7e-06	3.19e-05	CbGpPWpGaD
Vandetanib—EGFR—Immune System—TYK2—primary biliary cirrhosis	5.7e-06	3.18e-05	CbGpPWpGaD
Vandetanib—LCK—Signaling Pathways—CCL5—primary biliary cirrhosis	5.67e-06	3.17e-05	CbGpPWpGaD
Vandetanib—ALB—Metabolism—GOT2—primary biliary cirrhosis	5.67e-06	3.17e-05	CbGpPWpGaD
Vandetanib—ABCC1—Disease—TYK2—primary biliary cirrhosis	5.58e-06	3.12e-05	CbGpPWpGaD
Vandetanib—ABCG2—Metabolism—AGT—primary biliary cirrhosis	5.5e-06	3.07e-05	CbGpPWpGaD
Vandetanib—LCK—Signaling Pathways—RPS6KB1—primary biliary cirrhosis	5.5e-06	3.07e-05	CbGpPWpGaD
Vandetanib—LCK—Immune System—TYK2—primary biliary cirrhosis	5.49e-06	3.07e-05	CbGpPWpGaD
Vandetanib—SRC—Disease—NOS2—primary biliary cirrhosis	5.48e-06	3.06e-05	CbGpPWpGaD
Vandetanib—MAP2K5—Signaling Pathways—MMP9—primary biliary cirrhosis	5.4e-06	3.02e-05	CbGpPWpGaD
Vandetanib—MAP2K5—Signaling Pathways—NFKB1—primary biliary cirrhosis	5.35e-06	2.99e-05	CbGpPWpGaD
Vandetanib—PDGFRB—Immune System—NFKB1—primary biliary cirrhosis	5.33e-06	2.98e-05	CbGpPWpGaD
Vandetanib—SRC—Signaling Pathways—MMP3—primary biliary cirrhosis	5.32e-06	2.98e-05	CbGpPWpGaD
Vandetanib—SRC—Disease—CD80—primary biliary cirrhosis	5.32e-06	2.97e-05	CbGpPWpGaD
Vandetanib—KDR—Signaling Pathways—MMP9—primary biliary cirrhosis	5.27e-06	2.94e-05	CbGpPWpGaD
Vandetanib—EGFR—Disease—TYK2—primary biliary cirrhosis	5.26e-06	2.94e-05	CbGpPWpGaD
Vandetanib—PDGFRB—Signaling Pathways—CD80—primary biliary cirrhosis	5.24e-06	2.93e-05	CbGpPWpGaD
Vandetanib—LYN—Immune System—NFKB1—primary biliary cirrhosis	5.22e-06	2.92e-05	CbGpPWpGaD
Vandetanib—KDR—Signaling Pathways—NFKB1—primary biliary cirrhosis	5.21e-06	2.91e-05	CbGpPWpGaD
Vandetanib—ERBB3—Signaling Pathways—MMP9—primary biliary cirrhosis	5.21e-06	2.91e-05	CbGpPWpGaD
Vandetanib—ABL1—Immune System—NFKB1—primary biliary cirrhosis	5.19e-06	2.9e-05	CbGpPWpGaD
Vandetanib—ERBB3—Signaling Pathways—NFKB1—primary biliary cirrhosis	5.15e-06	2.88e-05	CbGpPWpGaD
Vandetanib—FYN—Immune System—NFKB1—primary biliary cirrhosis	5.14e-06	2.87e-05	CbGpPWpGaD
Vandetanib—LYN—Signaling Pathways—CD80—primary biliary cirrhosis	5.13e-06	2.87e-05	CbGpPWpGaD
Vandetanib—LCK—Disease—TYK2—primary biliary cirrhosis	5.07e-06	2.83e-05	CbGpPWpGaD
Vandetanib—FYN—Signaling Pathways—CD80—primary biliary cirrhosis	5.05e-06	2.82e-05	CbGpPWpGaD
Vandetanib—SRC—Signaling Pathways—CCL5—primary biliary cirrhosis	5.02e-06	2.81e-05	CbGpPWpGaD
Vandetanib—EGFR—Signaling Pathways—HIF1A—primary biliary cirrhosis	4.94e-06	2.76e-05	CbGpPWpGaD
Vandetanib—EGFR—Signaling Pathways—AGT—primary biliary cirrhosis	4.92e-06	2.75e-05	CbGpPWpGaD
Vandetanib—ALB—Metabolism—GGT1—primary biliary cirrhosis	4.89e-06	2.74e-05	CbGpPWpGaD
Vandetanib—ALB—Metabolism—GOT1—primary biliary cirrhosis	4.89e-06	2.74e-05	CbGpPWpGaD
Vandetanib—SRC—Signaling Pathways—RPS6KB1—primary biliary cirrhosis	4.87e-06	2.72e-05	CbGpPWpGaD
Vandetanib—SRC—Immune System—TYK2—primary biliary cirrhosis	4.86e-06	2.72e-05	CbGpPWpGaD
Vandetanib—ABCC1—Metabolism—ALB—primary biliary cirrhosis	4.8e-06	2.68e-05	CbGpPWpGaD
Vandetanib—LCK—Signaling Pathways—HIF1A—primary biliary cirrhosis	4.76e-06	2.66e-05	CbGpPWpGaD
Vandetanib—LCK—Signaling Pathways—AGT—primary biliary cirrhosis	4.75e-06	2.65e-05	CbGpPWpGaD
Vandetanib—VEGFA—Signaling Pathways—MMP9—primary biliary cirrhosis	4.73e-06	2.65e-05	CbGpPWpGaD
Vandetanib—VEGFA—Signaling Pathways—NFKB1—primary biliary cirrhosis	4.68e-06	2.62e-05	CbGpPWpGaD
Vandetanib—YES1—Signaling Pathways—MMP9—primary biliary cirrhosis	4.57e-06	2.56e-05	CbGpPWpGaD
Vandetanib—YES1—Signaling Pathways—NFKB1—primary biliary cirrhosis	4.52e-06	2.53e-05	CbGpPWpGaD
Vandetanib—SRC—Disease—TYK2—primary biliary cirrhosis	4.49e-06	2.51e-05	CbGpPWpGaD
Vandetanib—EGFR—Immune System—NFKB1—primary biliary cirrhosis	4.44e-06	2.48e-05	CbGpPWpGaD
Vandetanib—PDGFRB—Signaling Pathways—TYK2—primary biliary cirrhosis	4.42e-06	2.47e-05	CbGpPWpGaD
Vandetanib—EGFR—Signaling Pathways—CD80—primary biliary cirrhosis	4.36e-06	2.44e-05	CbGpPWpGaD
Vandetanib—ALB—Metabolism—PPARGC1A—primary biliary cirrhosis	4.36e-06	2.44e-05	CbGpPWpGaD
Vandetanib—LYN—Signaling Pathways—TYK2—primary biliary cirrhosis	4.33e-06	2.42e-05	CbGpPWpGaD
Vandetanib—LCK—Immune System—NFKB1—primary biliary cirrhosis	4.28e-06	2.39e-05	CbGpPWpGaD
Vandetanib—FYN—Signaling Pathways—TYK2—primary biliary cirrhosis	4.26e-06	2.38e-05	CbGpPWpGaD
Vandetanib—ABCG2—Metabolism—ALB—primary biliary cirrhosis	4.22e-06	2.36e-05	CbGpPWpGaD
Vandetanib—SRC—Signaling Pathways—HIF1A—primary biliary cirrhosis	4.22e-06	2.36e-05	CbGpPWpGaD
Vandetanib—LCK—Signaling Pathways—CD80—primary biliary cirrhosis	4.2e-06	2.35e-05	CbGpPWpGaD
Vandetanib—SRC—Signaling Pathways—AGT—primary biliary cirrhosis	4.2e-06	2.35e-05	CbGpPWpGaD
Vandetanib—CYP3A4—Metabolism—NUP210—primary biliary cirrhosis	3.87e-06	2.16e-05	CbGpPWpGaD
Vandetanib—SRC—Immune System—NFKB1—primary biliary cirrhosis	3.79e-06	2.12e-05	CbGpPWpGaD
Vandetanib—SRC—Signaling Pathways—CD80—primary biliary cirrhosis	3.72e-06	2.08e-05	CbGpPWpGaD
Vandetanib—EGFR—Signaling Pathways—TYK2—primary biliary cirrhosis	3.68e-06	2.06e-05	CbGpPWpGaD
Vandetanib—CYP3A4—Metabolism—ABCG2—primary biliary cirrhosis	3.6e-06	2.01e-05	CbGpPWpGaD
Vandetanib—LCK—Signaling Pathways—TYK2—primary biliary cirrhosis	3.55e-06	1.98e-05	CbGpPWpGaD
Vandetanib—PDGFRB—Signaling Pathways—MMP9—primary biliary cirrhosis	3.48e-06	1.95e-05	CbGpPWpGaD
Vandetanib—PDGFRB—Signaling Pathways—NFKB1—primary biliary cirrhosis	3.45e-06	1.93e-05	CbGpPWpGaD
Vandetanib—LYN—Signaling Pathways—MMP9—primary biliary cirrhosis	3.41e-06	1.91e-05	CbGpPWpGaD
Vandetanib—ALB—Metabolism—AGT—primary biliary cirrhosis	3.39e-06	1.9e-05	CbGpPWpGaD
Vandetanib—LYN—Signaling Pathways—NFKB1—primary biliary cirrhosis	3.37e-06	1.89e-05	CbGpPWpGaD
Vandetanib—FYN—Signaling Pathways—MMP9—primary biliary cirrhosis	3.36e-06	1.88e-05	CbGpPWpGaD
Vandetanib—FYN—Signaling Pathways—NFKB1—primary biliary cirrhosis	3.32e-06	1.86e-05	CbGpPWpGaD
Vandetanib—SRC—Signaling Pathways—TYK2—primary biliary cirrhosis	3.14e-06	1.76e-05	CbGpPWpGaD
Vandetanib—CYP3A4—Metabolism—CTGF—primary biliary cirrhosis	3.09e-06	1.73e-05	CbGpPWpGaD
Vandetanib—CYP3A4—Metabolism—GOT2—primary biliary cirrhosis	3.06e-06	1.71e-05	CbGpPWpGaD
Vandetanib—EGFR—Signaling Pathways—MMP9—primary biliary cirrhosis	2.9e-06	1.62e-05	CbGpPWpGaD
Vandetanib—EGFR—Signaling Pathways—NFKB1—primary biliary cirrhosis	2.87e-06	1.6e-05	CbGpPWpGaD
Vandetanib—LCK—Signaling Pathways—MMP9—primary biliary cirrhosis	2.8e-06	1.56e-05	CbGpPWpGaD
Vandetanib—LCK—Signaling Pathways—NFKB1—primary biliary cirrhosis	2.77e-06	1.55e-05	CbGpPWpGaD
Vandetanib—CYP3A4—Metabolism—GGT1—primary biliary cirrhosis	2.64e-06	1.48e-05	CbGpPWpGaD
Vandetanib—CYP3A4—Metabolism—GOT1—primary biliary cirrhosis	2.64e-06	1.48e-05	CbGpPWpGaD
Vandetanib—SRC—Signaling Pathways—MMP9—primary biliary cirrhosis	2.47e-06	1.38e-05	CbGpPWpGaD
Vandetanib—SRC—Signaling Pathways—NFKB1—primary biliary cirrhosis	2.45e-06	1.37e-05	CbGpPWpGaD
Vandetanib—CYP3A4—Metabolism—PPARGC1A—primary biliary cirrhosis	2.35e-06	1.31e-05	CbGpPWpGaD
Vandetanib—CYP3A4—Metabolism—AGT—primary biliary cirrhosis	1.83e-06	1.02e-05	CbGpPWpGaD
Vandetanib—CYP3A4—Metabolism—ALB—primary biliary cirrhosis	1.41e-06	7.86e-06	CbGpPWpGaD
